$Pluri Inc (PLUR.US)$ NEWS Unleashing the Power of MAIT Cell...
NEWS
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
Pluri Inc. launched a novel immunotherapy platform for solid tumor cancer treatment utilizing placental MAIT cells, a unique type of immune cells with great potential. Pluri's proprietary technology overcomes challenges in expanding MAIT cells, offering advantages over conventional T cells. The global cancer immunotherapy market is projected to reach $275.11 billion by 2032. Renowned cancer researchers Dr. Prasad S. Adusumilli and Dr. Richard L. Kendall joined Pluri's Scientific Advisory Board to support this groundbreaking platform.
Pluri Inc. launched a groundbreaking placental allogeneic MAIT cell platform for solid tumor immunotherapy.
MAIT cells demonstrate potent anti-tumor effects and lower alloreactivity, minimizing Graft versus Host Disease (GvHD) risks.
The global cancer immunotherapy market is forecasted to grow to $275.11 billion by 2032, presenting a significant market opportunity.
Renowned cancer researchers Dr. Prasad S. Adusumilli and Dr. Richard L. Kendall joined Pluri's Scientific Advisory Board, reflecting the platform's potential.
While MAIT cells show promise, challenges in commercial production and scalability may impact widespread adoption.
Despite advancements, uncertainties remain about the long-term efficacy and safety of MAIT cell immunotherapy.
Despite advancements, uncertainties remain about the long-term efficacy and safety of MAIT cell immunotherapy.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
789Followers
59Following
5170Visitors
Follow